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Abstract 
In the past decade, active surveillance (AS) of men with localized prostate cancer has become an 
increasingly popular management option, and a range of clinical guidelines have been published on this 
topic. Existing guidelines regarding AS for prostate cancer vary widely, but predominantly state that the 
most suitable patients for AS are those with pretreatment clinical stage T1c or T2 tumours, serum PSA 
levels <10 ng/ml, biopsy Gleason scores of six or less, a maximum of one or two tumour-positive biopsy 
core samples and/or a maximum of 50% of cancer per core sample. Following initiation of an AS 
programme, most guidelines recommend serial serum PSA measurements, digital rectal examinations and 
surveillance biopsies to check for and identify pathological indications of tumour progression. Definitions 
of disease reclassification and progression differ among guidelines and multiple criteria are proposed. The 
variety of descriptions of criteria for clinically insignificant prostate cancer indicates a lack of consensus 
on optimal AS and intervention thresholds. A single set of guidelines are needed in order to reduce 
variations in clinical practice and to optimize clinical decision-making. To enable truly evidence-based 
guidelines, further research that combines existing evidence whilst also gathering information from more 
long-term studies is needed.  
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Key points 
 A number of guidelines have been published that include criteria for active surveillance (AS) 
enrolment and subsequent management to assist clinicians and patients in critically important 
treatment related decision-making 
 Consensus on inclusion criteria, surveillance schedules and intervention thresholds is currently 
lacking 
 The future of AS and its uptake as a management modality will depend on better patient selection 
and validated monitoring schedules to improve identification of disease progression 
 Combining existing evidence and gathering more long-term evidence is needed to derive a 
broadly supported guideline to reduce variations in clinical practice and to optimize clinical 
decision-making  
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Introduction [H1] 
Prostate cancer is the second most common form of cancer and the sixth leading cause of cancer-related 
mortality among men worldwide, with an estimated 899,000 new cases and 258,000 deaths in 2008
1
. The 
numbers of men living with a diagnosis of prostate cancer will continue to increase as the populations of 
many countries continue to age, and cancer is detected earlier, owing to the more widespread use of 
serum PSA testing and extended prostate biopsy techniques
2
. Findings from studies of the effects of 
prostate cancer screening have demonstrated a decrease in cancer-specific mortality in longitudinal 
monitoring periods. According to the latest 13-year follow-up results of the European Randomized Study 
of Screening for Prostate Cancer (ERSPC), systematic serum PSA-based screening for prostate cancer can 
reduce the incidence of death from prostate cancer by 21% compared with the control cohort, where no, 
or limited, use of screening was reported
3
. Measurement of serum PSA level has been used as a screening 
test for prostate cancer for ≥20 years, although, the implementation of serum-PSA-based population 
screening remains controversial owing to the poor specificity of this biomarker, which frequently results 
in the incidental discovery of low-grade tumours that pose little risk of either metastatic spread or death
4, 
5, and are not likely to cause health problems during a man’s lifetime. Overtreatment is a well-recognized 
consequence of the overdetection of prostate cancer, and is particularly problematic in individuals who 
are at a low risk of aggressive or lethal disease, who might be exposed to the morbidities of treatment 
with little or no benefit in terms of cancer-specific survival
6
.  
Active surveillance (AS) focuses on the prevention of overtreatment by selecting patients with 
established features of low-risk prostate cancer and strictly monitoring these features over time in order to 
recognize a need for risk reclassification that would justify radical treatment, although still with a curative 
intent
7
. The current challenge is to identify the specific subset(s) of patients that harbour more-aggressive 
disease, at a sufficiently early stage that curative therapy remains a possibility, thereby allowing the 
majority of patients with prostate cancer to retain their current quality of life, without experiencing the 
adverse effects of unnecessary treatments
8
. 
  Various institution-specific eligibility protocols have been proposed for the identification of 
patients for whom active surveillance would be appropriate
2
. Currently, published reports that contain 
formal protocols for AS are available for 16 unique cohorts of men with prostate cancer, worldwide
9
. Use 
of many different AS protocols has been reported in the literature, although these vary in both their 
inclusion criteria and monitoring procedures
9
. To date, the effectiveness of AS protocols has not been 
validated in randomized controlled trials. More importantly, these protocols have not been examined with 
respect to their effects upon overall and/or prostate cancer-specific mortality outcomes
9
. A reliable 
method for identifying tumours that are clinically insignificant is still lacking and triggers for the 
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implementation of curative measures, such as radical prostatectomy and radiation treatments, have yet to 
be established.  
A number of guidelines have been published to assist both clinicians and patients in critically 
important treatment related decision-making, these include criteria for enrolment of patients in AS 
programmes and their subsequent management
10-25
. However, the comparability of the recommendations 
contained in these various guidelines is unknown. In this Review, existing guidelines on the use of AS in 
men with clinically insignificant prostate cancer are described and compared, including a comprehensive 
overview of the recommendations regarding patient selection, frequency and type of monitoring and the 
criteria for initiation of definitive treatment.  
 
[H1] Characteristics of the guidelines  
Half of all published guidelines on AS of men with prostate cancer identified in our literature search were 
developed in Europe (eight)
12, 14-19, 23
; three in Canada
10, 20, 24
; two in the USA
11, 13
; one in Asia
21
, one in 
New Zealand
22
 and one in Australia
25
 (Table 1). The guidelines were published between 2006 and 2015, 
and most of these have undergone subsequent updates. Most guidelines are published in English, except 
for the The Finnish Medical Society Duodecim (FCCG)23 and German Society of Urology (GSU)15 
guidelines, which were published in Finnish and German, respectively. Almost all guidelines were on the 
diagnosis, treatment and/or the management of patients with prostate cancer in general and included 
information on AS only as an alternative management strategy
10-17, 19-23, 25
. Two organizations, the South 
East Scotland Cancer Network (SCAN) 
18
 and Cancer Care Ontario (CCO) Evidence Based Guideline 
Quality Initiative
24
 have published guidelines that are specifically focused on AS. 
[H2] Quality assessment 
The Appraisal of Guidelines for Research and Evaluation (AGREE II) Instrument 
(http://www.agreetrust.org)
26
 is a validated generic tool designed for evaluation of the process of 
guideline development and provides a systematic framework for assessing key components of clinical 
guideline quality
27
. The instrument consists of 23 items grouped into six domains: scope and purpose; 
stakeholder involvement; rigour of development; clarity and presentation; applicability; and editorial 
independence
27
. One item is added to score the overall quality of the guideline. Each item is rated from 
one (strongly disagree or no information provided on this item) to seven (strongly agree)
27
. As outlined in 
the AGREE II manual, domain scores for AS protocols were calculated by summing all scores of the 
individual items in a domain, and by scaling the total as a percentage of the maximum possible score for 
that domain: ((obtained score – minimum possible score)/(maximum possible score – minimum possible 
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score))×100. Scores 60% were defined as ‘good’, scores of 30–60% as ‘moderate’ and scores lower than 
30% as ‘poor’ quality.  
According to this assessment, 12 of the guidelines are of ‘good’ quality: those provided by the American 
urological association (AUA)
13
; the European Association of Urology (EAU)
 14
; the National 
Comprehensive Cancer Network (NCCN)
 11
; the National Institute for Health and Clinical Excellence 
(NICE)
12
; the GSU
15
; the Belgian Healthcare Knowledge Centre (KCE)
 17
; the FCCG
23
; Cancer Care 
Nova Scotia (CCNS)
10
; Aragon Institute of Health Sciences (I+CS)
19
; CCO
24
; the Prostate Cancer 
Taskforce (PCT)
 22
; and the Prostate Cancer Foundation of Australia (PCFA)
25
, and four guidelines are of 
‘moderate’ quality: those provided by the Dutch Urological Association (DUA)16; the SCAN18; Alberta 
Health Services (AHS)
20
; and the Singapore Ministry of Health (NCCS)
21
. Inadequate and incomplete 
reporting cannot be ruled out as a reason for lower quality scores.  
 
[H2] Risk groups and surveillance  
Pretreatment risk estimation tools serve to stratify patients on the basis of perceived clinical risk and are 
employed in identifying candidates for AS. According to most of the guidelines described in this Review, 
patients with prostate cancer should be stratified into three risk groups: low, intermediate and high risk 
(Table 2), mostly based on tumour stage and grade, and serum PSA levels. The NCCN
11
 and the PCT
22
 
additionally included ‘very low risk’ as a suitable risk profile of patients who are eligible for AS. 
According to recommendations contained in all guidelines included in this Review, AS is primarily 
recommended for patients with low-risk tumors. Various definitions of low-risk prostate cancer exist in 
these guidelines, as specified by different combinations of clinical criteria including clinical and 
pathological characteristics (such as tumour stage, serum PSA levels, biopsy Gleason score, tumor 
volume and serum PSA density). In certain guidelines, patients must possess numerous concurrent low-
risk features in order to be classified as ‘low-risk’, although in others, certain individual clinical criteria 
might lead to a patient being classified as having an intermediate, or high risk of tumour progression. Five 
guidelines, those provided by the AUA
13
, NICE
12
, DUA
16
, FCCG
23
, and CCNS
10
,  contain 
recommendations to select intermediate-risk patients with prostate cancer for AS. Two of these guidelines 
— from the AUA13 and the DUA16 — state that AS also remains a treatment option for patients with 
‘high-risk’ prostate cancer. Both of these guidelines specifically refer to AS and not to watchful waiting. 
In the AUA guidelines
13
, the term ‘active surveillance’ is used to refer to a monitoring program without 
initial treatment for patients with localized prostate cancer. This monitoring programme and its goals 
might be different based on specific patient and tumour characteristics and is distinct from watchful 
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waiting, in which a lesser degree of monitoring is typically used, and treatment is generally instituted if 
metastases or symptoms develop
13
. The DUA guidelines
16
 also acknowledge a meaningful difference 
between AS and watchful waiting. In active surveillance, curative treatment is recommended if disease 
progression is detected, however, in watchful waiting the decision to start treatment relies on the 
progression of symptoms. The watchful waiting approach is typically used for the management of older 
patients who have substantial comorbidities. The DUA guidelines
16
 contain the recommendation that AS 
can be considered for patients with intermediate-risk or high-risk prostate cancer if the age of the patient 
and/or his comorbidities negatively influence life expectancy. According to the AUA guidelines
13
, 
patients with high-grade tumours generally have a poor prognosis and are not suitable for AS however, 
AS remains an option for the management of patients with high-risk localized prostate cancer, owing to 
the lack of evidence of superiority of any one therapy over another. 
[H1] Eligibility for active surveillance 
[H2] Tumour characteristics  
[H3] Clinical stage  
All of the guidelines described in this Review include information regarding the clinical stage of the 
prostate tumour as an eligibility criterion for AS. According to six of the guidelines, (those provided by 
the NCCN
11
, KCE
17
, NCCS
21
, I+CS
19
, CCO
24
 and PCT
22
), AS is acceptable for patients with any tumours 
of stages T1 and T2a and also, according to the GSU guidelines
15
, for patients with tumours of stages T1c 
and T2a. The EAU guidelines
14
 include patients with stage T1c and any stage T2 tumours as being 
eligible for AS; the SCAN guidelines
18
 recommend inclusion of only patients with stage T1c tumours and 
the AHS guidelines
20
 recommend including those with ≤T2b stage tumours. Two guidelines (provided by 
NICE
12
 and the FCCG
23
) contain recommendations that patients with stage T2b tumours should be 
considered eligible for AS and three guidelines (provided by the AUA
13
, CCNS
10
 and PCFA
25
) also 
contain recommendations that patients with stage T2b–T2c tumours are eligible. The DUA guidelines16 
also contain recommendations for use of AS (not watchful waiting), in patients with stage T3 tumours.  
[H3] Serum PSA 
All of the guidelines contain serum PSA-based criteria for eligibility for AS. Ten of the guidelines report 
a cutoff of 10 ng/ml, above which, AS is not considered appropriate; seven of the guidelines (those 
provided by the NCCN
11
, KCE
17
, SCAN
18
, AHS
20
, CCO
24
, NCCS
21
 and the PCT
22
) are exclusive, and 
three (those provided by the EAU
14
, GSU
15 
and I+CS
19
) are inclusive of this threshold. Three guidelines 
(those provided by NICE
12
, FCCG
23
 and PCFA
25
) also consider patients with serum PSA levels of 10–20 
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ng/ml to be eligible for AS and the CCNS guidelines
21
 include the same recommendation at 10–19 ng/ml 
serum PSA. The AUA
13
 and DUA
16
 guidelines  allow selection of patients with serum PSA levels >20 
ng/ml for AS. Finally, five of the guidelines (those provided by the NCCN
11
, SCAN
18
, I+CS
19
, NCCS
21 
and PCT
22
) include PSA density, which is the total serum PSA divided by the prostate volume, as an 
inclusion criterion for active surveillance, using a cutoff of <0.15 ng/ml
2 
.  
[H3] Biopsy Gleason score  
All of the guidelines described in this Review recommend Gleason score of a patient’s biopsy sample(s) 
as a criterion for inclusion in AS programmes. Of these, 10 guidelines allow patients to have a Gleason 
score of ≤6 (those provided by the EAU14, NCCN11, GSU15, I+CS19, NCCS21, PCT22 and PCFA25) or, 
presented differently, <7 (those provided by the KCE
17
 and AHS
20) or ≤3+3 (the SCAN guidelines18). 
Four guidelines, those provided by NICE
12
, CCNS
10
, CCO
24
,
 
and the FCCG
23
, consider patients with a 
Gleason score of 7 (mainly 3+4) eligible for AS and two guidelines support selection of patients with a 
Gleason score of >7 (those provided by the AUA
13
 and DUA
16
).  
[H3] Tumour Volume 
11 guidelines combine Gleason score, clinical tumour stage and serum PSA values with estimates of 
tumour load from analysis of biopsy specimens when considering patients for AS. Of the nine guidelines 
that include a recommendation based on the number of tumour-positive biopsy core samples, eight of 
these recommend a maximum of one or two tumour-positive biopsy core samples, either expressed as <3 
(those provided by the NCCN
11
, FCCG
20
, NCCS
26 
and PCT
27
), one or two positive core samples (the 
DUA
16
) or ≤2 (the AUA25, EAU14 and GSU15). One guideline (from the AHS20) suggests that patients 
with three tumour-positive biopsy cores should be considered eligible for AS.  
  Nine guidelines include the maximum extent of cancer, per biopsy core sample, as an inclusion 
criteria for active surveillance. All guidelines containing any consideration of the maximum extent of 
cancer use a cutoff of 50%, of which three contain recommendations that are exclusive (those provided by 
the SCAN
18
, I+CS
19
 and PCT
27
) and six that are inclusive of the threshold value (those provided by the 
AUA
13
, EAU
14
, NCCN
11
, GSU
15
, AHS
20
 and NCCS
21
).Three guidelines ( those provided by the AUA
13
, 
I+CS
19
, and AHS
20
) additionally state that a minimum of 10 prostate biopsy cores should be sampled and 
two guidelines ( those provided by the GSU
15 
and FCCG
23
) recommend a minimum core biopsy sample of 
10–12 cores.  
[H3] Patient characteristics  
Three guidelines (those provided by the DUA
16
, FCCG
23
 and SCAN
18
) include the patient’s age as an 
inclusion criteria for active surveillance. The SCAN
18
 recommends a threshold of ≤75years, the FCCG23 
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guidelines refer to age as one of the variables to be considered when estimating patients life expectancy, 
and the DUA
16
 state that use of active surveillance is negotiable, if the age of the patient and his 
comorbidities negatively influence life expectancy.  
  Eight guidelines (those provided by the EAU
14
, NCCN
11
, DUA
16
, KCE
17
, FCCG
23
, SCAN
18
, 
NCCS
21
 and PCT
22
)  include the patient’s life expectancy as an inclusion criterion. All of these guidelines 
apply a cut-off time of 10 years. Most guidelines (including those provided by the (EAU
14
, NCCN
11
, 
KCE
17
 and SCAN
18
) describe a life expectancy of >10 years as the ideal indication criterion for AS of 
patients with (very) low-risk prostate cancer. The EAU
14
 guidelines state that the patient’s life expectancy 
can exceed 10 years once patients are informed of the lack of data on survival beyond 10 years. One set of 
guidelines (provided by the NCCS
21
) recommends use of AS in men with a shorter life expectancy, 
specifically <10 years. The other three guidelines (those provided by the DUA
16
, FCCG
23
 and PCT
22
) 
state that the patient’s life expectancy should be taken into account, but do not provide further details.  
  Six guidelines (those provided by the AUA
13
, DUA
16
, FCCG
23
, I+CS
19
, NCCS
21
 and PCT
22
) 
advise consideration of the presence of medical comorbidities and patients’ bowel and genitourinary 
function, and quality of life status, in the decision making process
13, 16, 19, 21-23
. Finally, eight guidelines 
(those provided by the AUA
13
, NICE
12
, KCE
17
, FCCG
23
, I+CS
19
, AHS
20
, NCCS
21
 and PCT
22
) state that 
the decision to start AS should be made in the light of the patient’s individual preferences.  
[H2] Summary of eligibility criteria  
Multiple criteria have been proposed for identifying patients with prostate cancer who have a favourable 
prognosis and are, therefore, candidates for AS (Table 3). Most available international guidelines 
recommend clinical risk stratification based on patients’ tumour stage, serum PSA level, Gleason score, 
and estimated tumour volume as the primary means of refining patient selection. PSAD, the minimum 
number of prostate biopsy cores acquired, the patient’s life expectancy, the presence of comorbidities and 
the patient’s preferences have been advanced by some but have not, thus far, been universally adopted as 
risk stratification tools. Many variations in risk stratification schemes currently exist, guidelines 
predominantly recommend that the most suitable patients for active surveillance are those with 
pretreatment clinical stage T1(c) or T2a prostate cancer, serum PSA <10 ng/ml, biopsy Gleason score of 
six or less, a maximum of one or two tumour-positive biopsy core samples and/or a maximum of 50% of 
cancer per core. 
[H1] Surveillance type and frequency  
Of the 16 guidelines included, three guidelines (those provided by the AUA
13
, DUA
16
 and PCFA
25
) do not 
provide explicit recommendations for the monitoring of patients as part of an AS programme.  
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[H2] Serum PSA measurements  
Thirteen of the guidelines described in this Review recommend measurements of serum PSA during AS 
procedures. Four guidelines (those provided by the NCCN
11
, KCE
17
, CCNS
10
 and PCT
22
) state that serum 
PSA monitoring should be implemented at intervals longer than every 6 months after the start of AS. The 
PCT
22
 guidelines additionally state that serum PSA levels should be measured every 3 months if concerns 
about progression of the cancer exist. Three guidelines (those provided by the AHS
20
, CCO
24
 and 
NCCS
21
) recommend serum PSA testing every 3–6 months after the start of AS, whereas four of the other 
guidelines (those provided by NICE
12
, GSU
15
, SCAN
18
 and I+CS
19
) use different frequencies depending 
on the time that has passed since the start of AS . Two of these guidelines (those provided by the GSU
15
 
and SCAN
18
) state that serum PSA should be measured every 3 months in the initial testing period of 1 
year, and if the PSA level is stable within this period, then every 6 months subsequently. The I+CS
19
 
guidelines recommend a serum PSA test every 3 months in the initial testing period of 2 years, and if the 
serum PSA level is stable within this period, then every 6 months subsequently. The NICE
12
 guidelines 
state that serum PSA levels should be checked every 3–4 months in the first year after commencing AS, 
and then every 3–6 months between 2–4 years and every 6 months in year 5 and thereafter. Finally, two 
guidelines (those provided by the EAU
14
 and FCCG
23
) recommend serum PSA testing during AS, but do 
not suggest any specific interval lengths between measurement.  
[H2] Digital rectal examination 
Thirteen of the guidelines described in this Review recommend the use of a digital rectal examination 
(DRE) in order to monitor the tumour carefully during a programme of AS. Four guidelines (those 
provided by the NCCN
11
, AHS
20
, CCO
24
 and NCCS
21
) recommend DRE at an interval of no more than 
once every 12 months. Another four guidelines (those provided by the KCE
17
, SCAN
18
, CCNS
10
 and 
PCT
22
) suggest more frequent DRE — every 6 months. The PCT guidelines22 additionally recommend 
that DRE should be performed every 3 months if concerns exist regarding tumour progression. Similar to 
serum PSA measurements, three guidelines (those provided by NICE
12
, GSU
15
 and I+CS
19
) recommend 
the use of different intervals between successive DREs depending on the time that has passed since the 
start of AS. The NICE guidelines
12
 recommend that a DRE should be conducted every 6–12 months if 
patients have low-risk prostate cancer, and are undergoing AS within the first four years of diagnosis, 
with an annual DRE subsequent to this 4-year period. Two guidelines (provided by the GSU
15
 and 
I+CS
19
) recommend a DRE every 3 months in the first 2 years after diagnosis, subsequently reducing to 
DRE at 6-monthly intervals thereafter (provided that serum PSA levels remain stable). Finally, two 
guidelines (those provided by the EAU
14
 and FCCG
23
) recommend use of DRE during active surveillance, 
but do not suggest any specific interval lengths between examinations. 
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[H2] Repeat biopsy sampling  
Repeat prostate biopsy sampling is used during AS in order to limit sampling error of the initial biopsy, 
that is, to confirm the initial biopsy findings and, periodically, to evaluate pathological progression of the 
tumour grade and/or volume, which might influence prognosis and, hence, the decision to continue AS or 
to proceed to definitive local therapy. 
Substantial variation exists in the recommended frequency at which rebiopsy procedures should be 
conducted. A total of 13 of the guidelines described in this Review provide guidance in this area. The 
NCCN guidelines
11
 recommend intervals between biopsy sampling of at least 12 months, unless clinically 
indicated, or at 6 months if the initial biopsy procedure involved sampling of <10 cores or assessment 
discordant (e.g. palpable tumour contralateral to side of positive biopsy). Three guidelines (those provided 
by NICE
12
, KCE
17
 and the PCT
22
) recommend rebiopsy sampling at or within one year of diagnosis. 
According to the NICE
12
 and PCT guidelines
22
, the frequency of rebiopsy sampling should be dictated by 
changes in serum PSA levels or clinical concerns of tumour progression based on prostate changes 
detected by DRE. The KCE guidelines
17
 recommend the use of repeat biopsy sampling procedures, but 
also suggest that the optimal timing of such procedures cannot currently be defined. Seven guidelines 
(those provided by the GSU
15
, SCAN
18
, CCNS
10
, I+CS
19
, AHS
20
, CCO
24
 and NCCS
21
) recommend 
different frequencies of rebiopsy sampling depending upon the time that has passed since the start of AS. 
The AHS guidelines
20
 recommend repeat biopsy sampling at an interval of 1–2 years after the original 
diagnosis, and then every 2–3 years thereafter, or as clinically indicated. The SCAN guidelines18 
recommend considering rebiopsy sampling within 6 months of diagnosis, and then after 1, 4, 7 and 10 
years of AS. The I+CS guidelines
19
 recommend rebiopsy sampling using a 1, 4 and 7 year timeframe, 
with at least 10 cores taken per biopsy procedure. The CCO guidelines
24
 recommend rebiopsy sampling 
with a 12–14-core confirmatory transrectal ultrasonography (TRUS) biopsy procedure (including 
anterior-directed cores) within 6–12 months of diagnosis, and serial biopsy a minimum of every 3–5 years 
thereafter. The NCCS guidelines
21
 suggest the use of rebiopsy sampling within 12–18 months and then 
less frequently thereafter. The EAU guidelines
14
 state that surveillance should, amongst other factors, be 
based upon the findings of repeat biopsy sampling , although the optimal timing of the various clinical 
measurements taken during AS is still unclear. Finally, the FCCG guidelines
23
 recommend use of repeat 
biopsy sampling during surveillance, but do not suggest any specific lengths of intervals between 
procedures.  
[H2] Other surveillance measures   
[H3] PSA kinetics  
11 
 
Seven guidelines (those provided by NICE
12
, GSU
15
, FCCG
23
, SCAN
18
, I+CS
19
, AHS
20
 and the PCT
22
) 
recommend including measurements of serum PSA kinetics in AS protocols, although  none describe 
specific cut-off values. For example, the NICE guidelines
12
 state that serum PSA kinetics — which 
include PSA doubling time (PSADT) and PSA velocity (PSAV) — should be measured throughout AS, 
from the first year until 5 years and thereafter. The SCAN guidelines
18 
recommend calculating PSADT 
using a specific tool developed at the Memorial Sloan Kettering Cancer Center 
(https://www.mskcc.org/nomograms/prostate ), although only after five measurements of serum PSA 
levels have been obtained, including a measurement of baseline serum PSA. 
[H3] MRI  
According to four guidelines (those provided by the NCCN
11
, NICE
12
, KCE
17
 and CCO
24
), MRI might be 
considered for routine use in AS. According to the NCCN guidelines
11
, MRI may be performed in 
patients whose serum PSA levels have increased, despite the biopsy sample being found to be tumour-
negative on analysis. The NICE guidelines
12
 recommend that multiparametric MRI (mpMRI) should be 
performed at enrolment, (if not previously performed) or if the clinician is concerned about changes in 
clinical parameters or serum PSA levels at any time during AS. The KCE guidelines
17
 state that use of 
imaging can be considered each year. The CCO guidelines
24
 suggest that use of mpMRI is indicated when 
a patient’s clinical findings are discordant with the pathological findings, and that MRI is useful in 
identifying occult cancers or changes indicative of tumour progression in patients who are at risk. 
[H2] Summary of surveillance type and frequency  
Following initiation of AS, most guidelines recommend serial measurment of serum PSA levels, digital 
rectal examination and surveillance biopsy sampling in order to identify pathological progression. 
However, many uncertainties remain surrounding the optimal timing of these surveillance strategies. PSA 
kinetics and MRI are less frequently recommended  as methods to identify whether or not a patients’ 
cancer has progressed (Table 4). 
[H1] Switching to definitive therapy 
A proportion of men with ostensibly low-grade, low-stage prostate cancer who are undergoing AS will 
experience changes that will indicate a need for disease reclassification during extended surveillance
28, 29
. 
As men’s symptoms progress, or are reclassified beyond the initial inclusion criteria for active 
surveillance (they no longer meet the entry criteria), treatment with curative intent is often recommended. 
Definitions of tumour progression or reclassification vary among the published guidelines and a number 
of criteria have been proposed for determining when to proceed with curative interventions (Table 4). 
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Five of the guidelines described in this study (those provided by the AUA
25
, EAU
14
, DUA
16
, PCT
27
 and 
the PCFA
10
) do not include criteria for switching from AS to definitive therapy.  
[H2] Serum PSA measurements 
Two guidelines (those provided by the GSU
15
 and KCE
17
) describe an increase in serum PSA >10 mg/ml 
as a trigger for intervention. According to these, and a further four guidelines (those provided by the 
FCCG
23
, SCAN
18
, I+CS
19
 and AHS
20
), changes in PSA kinetics can be assumed to be indicative of 
tumour progression. In five guidelines (those provided by the GSU
15
, KCE
17
, FCCG
23
, SCAN
18
 and 
AHS
20
) PSADT is recommended as a trigger for definitive intervention: all of these guidelines 
recommend commencing active treatment if PSADT is shorter than 3 years. One guideline describes PSA 
velocity as a trigger for intervention: if PSAV is >1 ng/ml per year, then active treatment should be 
initiated.  
[H2] Digital rectal examination 
Five guidelines (those provided by the GSU
15
, SCAN
18
, I+CS
19
, AHS
20
 and NCCS
21
) include clinical 
progression, as confirmed by DRE as a trigger for switching from AS to treatment. According to the 
SCAN guidelines
18
, a finding of progression of palpable T2-stage disease on DRE or the appearance of 
palpable lesions is a criterion for intervention. The GSU
15
 recommends treatment if the clinical stage of 
the tumour increases to >cT2a. Four guidelines more generally state that treatment should be 
recommended: if there is an increase in clinical stage from baseline status (AHS
20
), if an abnormal finding 
or change is detected on DRE (NCCS
21
), if a clinical change is detected, in general, during DRE (KCE
17
), 
or if locally advanced disease is detected during a DRE (I+CS
19
).  
 
[H2] Reclassification of biopsy sample grade  
Of all guidelines considered in this Review, eight (those provided by the NCCN
30
, GSU
15
, FCCG
23
, 
SCAN
18
, I+CS
19
, AHS
20
, CCO
24
 and NCCS
21
) describe changes in the Gleason score of a prostate biopsy 
sample as a potential trigger for switching from surveillance to active therapy. According to four of these 
guidelines (those provided by the NCCN
11
, SCAN
18
, AHS
20
 and NCCS
21
), the appearance of primary or 
secondary Gleason 4 or any Gleason 5 pattern on rebiopsy is an indication to cease AS and consider 
intervention. Additionally, the GSU
15
, FCCG
23
 and NCCS guidelines
21
 recommend that all patients 
undergoing AS who are found to have a biopsy Gleason score of 6 (such as ≥3+4 on analysis of a repeat 
biopsy sample should be considered for switching to active therapy. The CCO
 
guidelines
24
 state that for 
patients with a Gleason score of ≥7 and/or who also have substantial increases in the volume of Gleason 6 
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tumour detected on analysis of a rebiopsy sample consideration should be given to switching to active 
therapy. The I+CS guidelines
19
 more generally recommend treatment in men with a higher degree and/or 
larger tumour volume observed in repeat biopsy samples relative to previous biopsy samples. 
[H2] Increase in tumour volume 
Three guidelines, those provided by the GSU
15
, FCCG
23
 and NCCS
21
, state that treatment should be 
recommended in men who have >2 tumour-positive biopsy sample cores; and four guidelines (those 
provided by the GSU
15
, SCAN
18
, AHS
20
 and NCCS
21
) recommend that the extent of the cancer should not 
exceed 50% per core, if AS is to be continued. The SCAN guidelines
18
 additionally recommend that 
≤50% of the total number of cores should be affected by a patient’s cancer for continued use of AS. Two 
guidelines (those provided by the NCCN
30
, and I+CS
19
) contain more general descriptions. The NCCN 
guidelines state that an increase in the number of tumour-positive biopsy sample cores or an increase in 
the extent of disease in tumour-positive sample cores upon rebiopsy is a trigger for switching to 
treatment. The I+CS guidelines
19
 suggest a greater extension of the tumour in repeated biopsies. Four of 
the guidelines described in this Review (those provided by the AUA
13
, GSU
15
, I+CS
19
 and AHS
20
) include 
information on the minimum number of biopsy cores that should be sampled and all agree on a minimum 
number of 10 cores. 
[H2] Other recommendations 
Two guidelines (those provide by NICE
12
 and the NCCS
21
), in general, recommend initiation of active 
treatment if disease progression is observed. Furthermore, the FCCG guidelines
23
 simply state that active 
treatment is recommended if a man’s prostate cancer is reclassified as being clinically relevant. 
According to three guidelines (those provided by NICE
12
, the AHS
20
 and NCCS
21
), the decision to 
proceed to radical treatment should be made on the basis of personal preferences
12, 20, 21
. According to the 
NICE guidelines
12, the individual man’s specific comorbidities and life expectancy should be taken into 
account when making a decision on proceeding to treatment.  
[H2] Summary of switching criteria  
Several of guidelines described in this Review do not include any criteria on switching from AS to 
definitive therapy. Definitions of disease reclassification and progression differ between different 
guidelines, and multiple criteria for initiation of treatment are proposed (Table 5). Some guidelines 
advocate the initiation of curative treatment if progression to a higher-grade tumour (mainly described as 
Gleason pattern 4 or 5) is observed, or if an increase in the number of tumour-positive biopsy cores (>2 of 
a recommended minimum of 10 cores) or an increase in the extent of cancer per core sample (to >50% of 
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cancer per tumour-positive core) is detected on analysis of surveillance biopsy samples. Clinical 
progression detected during DRE (although currently not clearly defined), a serum PSADT of 3 years, or 
a change in patient preference are also regularly described as risk reclassification criteria, leading to 
initiation of definitive treatment. 
[H1] Considering protocols overall 
In light of the high global prevalence of localized prostate cancer, AS has been widely implemented and 
numerous agencies have endorsed practice guidelines in this area. In total, 16 international guidelines 
advocate the use of AS as an initial option for disease management in men with localized prostate cancer, 
but many variations in recommended risk stratification schemes are found. Guidelines predominantly 
state that the most suitable patients for AS are those with pretreatment clinical stage T1(c) or T2 prostate 
cancer, serum PSA levels <10 ng/ml, biopsy Gleason scores of 6 or less, a maximum of one or two 
tumour-positive biopsy core samples and/or a maximum of 50% of cancer per biopsy core sample. 
Following initiation of AS, most guidelines advise the use of serial serum PSA measurements, DRE and 
surveillance biopsies to identify pathological tumour progression. The recommended intervals between 
these tests vary widely between guidelines. Definitions of disease reclassification and progression 
differed among guidelines and multiple criteria are proposed (Table 6). 
  AS  is increasingly being accepted as a treatment option for patients with localized prostate 
cancer, although, robust data from men with clinically insignificant prostate cancer who are undergoing 
active surveillance guided by various protocols — especially from studies with long follow-up durations 
— is still limited. At present, two prospective AS studies have reported long-term outcomes of men with 
favorable-risk prostate cancer
31, 32
. New data from the Johns Hopkins on outcomes after AS showed that 
factors associated with curative intervention were prostate specific antigen density at diagnosis and a 
higher number of positive biopsy cores at diagnosis 
31
. Klotz et al found that in a Canadian active 
surveillance cohort, followed up for 16 years, PSADT of less than 3 years is a marker for aggressive 
disease
32
. Further, only data from prospective clinical trials of active surveillance, that have a mean 
follow-up duration of 10 years are available33. This lack of robust evidence is reflected in the diversity 
of recommendations among the available guidelines on AS of men with clinically insignificant prostate 
cancer. Findings of a study conducted by Azmi et al.
34
 in 2013 showed that a relatively high level of 
agreement exists between the conclusions of various studies of AS that patients with serum PSA levels 
≤10 ng/ml and a biopsy sample Gleason score of ≤3+3 = 6 are appropriate for AS, although, clearly less 
agreement exists in terms of the most appropriate clinical tumour stage, number of tumour-positive 
biopsy core samples and patient age
34
. Furthermore, little consensus exists in the literature regarding how 
to optimally assess progression of localized prostate cancer; although, the majority of studies used serial 
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measurements of serum PSA levels and DRE, with some also adding prostate biopsy sampling
34
. No 
consensus has been reached regarding the frequency of repeat investigations or on the most appropriate 
triggers for initiation of radical treatment across the various AS programmes
34
. To enable truly evidence-
based guidelines to be issued, further research that combines existing evidence whilst also gathering 
information from more long-term studies is needed.  
 Patients with prostate cancer who have a tumour grade of Gleason ≤6 are extremely unlikely to 
progress to metastatic disease or die from their cancer
35
. However, some guidelines have taken the 
position that AS  could be an appropriate management strategy for men with a Gleason score of ≥7 at 
diagnosis
10, 12, 13, 16, 23, 24
. Findings from a study with a large cohort demonstrate that the finding of a 
Gleason score of 8–10 on confirmatory biopsy is associated with early progression to metastasis32. The 
AUA guidelines
13
 acknowledge these high rates; however, these guidelines still recommend AS as a 
treatment option for patients with high-risk disease owing to the lack of evidence of superiority of any 
one therapy over another. Whether this approach is the correct one to follow is a matter of some debate.  
  Explanations for the observed variations between available guidelines for AS are speculative, but 
geographical variations should be taken into account. Different countries practice medicine in various 
ways and vary particularly in their approaches to the treatment of cancer
36
. These differences are likely a 
result of the existence of distinct national cultures, history and medical training
36
. For instance, major 
differences exist between the detection and treatment of prostate cancer in the USA and UK. Widespread 
use of serum-PSA based screening in the USA has resulted in a higher proportion of men being diagnosed 
with disease that is amenable to AS
37, 38
. In the UK — a country with relatively limited use of serum-PSA 
based screening — only a small minority of newly diagnosed patients with prostate cancer meet the 
criteria for low-risk disease
39
. An aggressive local philosophy with respect to prostate cancer screening 
might also correspond with an increased tendency towards treatment
40
. In the USA, academic medical 
community and professional societies have become more accepting of AS for men with low-risk prostate 
cancer, although delaying the initiation of aggressive treatment is still not generally acceptable to most 
patients or their doctors
38
. By contrast, findings of a UK study published in 2010 showed that British men 
and doctors were more willing to accept AS with up to 39% opting for AS in recent years
39
. The various 
available guidelines highlight the best practices for the diagnosis, treatment and/or the management of 
prostate cancer in different geographical areas. Whether or not these cross-cultural differences will ever 
be perfectly integrated into one global policy remains questionable.  
  The validation and clinical implementation of novel biomarkers might improve the identification 
of the most appropriate candidates for AS and will likely be reflected in future guidelines. Van den Bergh 
et al
41
 concluded that imaging and serum-based markers (such as PSA isoforms) might, in the future, 
improve the selection of patients for AS and follow-up monitoring during active surveillance
41
. In a 
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review published in 2014, authors noted that a growing body of literature is available on patient 
characteristics, biopsy features and biomarkers with potential utility in AS
42
. For instance, patient age, 
race, and possibly family history are all factors that could be considered for patient selection. Also, 
consistent evidence suggests that a lower percentage free PSA, higher Prostate Health Index, higher 
PSAD and greater biopsy core involvement at baseline all indicate a greater risk of progression 
42
. 
Furthermore, evidence suggests that use of the biopsy-based 17-gene Genomic Prostate Score improves 
prediction of the presence or absence of adverse pathology and might help men with prostate cancer to 
make better-informed choices between AS and immediate treatment
43
. Following various advances in 
genomic and proteomic technologies, several new Clinical Laboratory Improvement Amendment-based 
laboratory-developed tests have become available that might also be useful in the differentiation of 
aggressive from nonaggressive forms of prostate cancer, such as Prolaris
®
 (Myriad Genetics, Salt Lake 
City, UT USA)
44
. The 4Kscore
®
 (Opko Health, FL, USA) has also been shown to have proven diagnostic 
performance when used for detection of clinically significant prostate cancer and might be a useful tool in 
distinguishing men who have clinically significant disease and are most likely to benefit from a prostate 
biopsy from men with no cancer or indolent cancer
45
. In a systematic review on the use of MRI in men 
with low-risk or intermediate-risk prostate cancer who were considered suitable for AS, the researchers 
demonstrated that MRI is useful for the detection of clinically significant disease at initial clinical 
assessment of men considering AS
46
. In addition, MRI might be useful to confirm the absence of any 
large anterior lesions that have been missed during routine diagnosis
47
. However, at present, no robust, 
formally published data are available that support the use of MRI in place of repeat standard biopsy 
sampling to detect progression of cancer over time
46
. Among biopsy sampling approaches, transrectal 
prostate biopsy sampling (TRB) is internationally more common than transperineal prostate biopsy 
sampling (TPB). Findings of a study published in 2013, however, suggest that, in patients on AS 
programmes, a staging TPB might be an alternative approach for patients undergoing repeat biopsy in 
order to minimize the risk of serious infection
48
. Whether any role exists for these markers and monitoring 
tools in risk assessment during AS requires further study. . Finally, quality of life, arguably, should have a 
role in the decision to initially pursue AS rather than active treatment and in the decision to switch from 
AS to active treatment
49
. However, no data from studies with long-term follow-up durations and suitable 
control groups are currently available and more research is needed in this area. AS is currently an 
evolving treatment approach, with numerous challenges (Box 2). Thus, it is advised that guideline writers 
should carefully follow the progress that is made within the field of AS, as the field is moving rapidly.  
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[H1] Challenges in reviewing AS guidelines 
The use of electronic sources to identify guidelines for discussion in this Review might have introduced 
bias towards English language guidelines and guidelines produced by larger, well-established 
organizations
50
. The use of high-quality guidelines  would improve  health-related decision making, 
potentially resulting in enhanced health care quality and outcomes. Our own assessment using the 
AGREE II tool suggests that not all of the included guidelines are of ‘good’ quality. It could be argued if 
guidelines of ‘moderate’ quality should be used for patient care. Users of clinical practice guidelines need 
to know how much confidence they can place in the recommendations. Furthermore, the guidelines 
described in this Review have been developed by a number of leading organizations using different 
methodologies. For instance, discrepancies exist in the criteria used to grade the quality of evidence and 
to categorize the strength of the recommendations. These differences could be the source of conflicting 
recommendations
51
. Standardizing the processes used by leading urological organizations to develop 
clinical guidelines for the management of patients with prostate cancer would be beneficial to both 
clinicians and patients (Box 3)
51
. Finally, substantial variation was observed in the year of publication of 
individual sets of  guidelines, with several were published more than 5 years ago, which could mean these 
are no longer in line with current clinical practice, thus leaving it up to clinicians to make up their own 
minds about how they manage patients on AS.  
 
[H1]Future steps   
Clearly, an unmet need exists for a worldwide consensus regarding criteria and protocols for AS. When 
developing a global guideline, the selection of topics, the composition of the guideline group, the work 
plan, the search for evidence and the involvement of clinical experts are all important
52
. An evidence-
based consensus approach to developing guideline recommendations is considered the ‘gold standard’. 
The development phase should, therefore, start by searching for scientific evidence and an assessment of 
its relevance and quality. As a next step, clinical experts should be involved to formulate and prioritize 
recommendations
52
. Owing to the possibility of one, or a few experts could dominating discussions 
according to their own individual origin, background and experiences, structuring the discussions is 
recommended, for instance by using the Delphi Procedure
53
 to quantitate ‘expert opinion’. The entire 
process of developing guidelines should be transparent to the guideline user. The principal benefit of a 
global guideline is to improve the consistency of (high-quality) care. However, constructing a global 
guideline presents a unique challenge. Approaches to AS of men with prostate cancer differ across the 
world, the guideline should, therefore be both comprehensive and flexible enough to allow adaptation to 
the diverse settings and circumstances of day-to-day clinical practice. The development and publication of 
a set of global clinical practice guidelines are only the first steps in the process of improving patient care. 
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To facilitate the applicability of such guidelines in daily care, co-operation with professional societies and 
associations is crucial. The clinical guideline should ideally be submitted for approval to an independent 
scientific council and to the professional urological organizations responsible
52
. Furthermore, 
collaboration should be sought with patient advocacy organizations, who could have an important role in 
promoting the guidelines among patients and their families.  
One potential solution is the Movember Global Action Plan Active Surveillance project (GAP3), which 
was launched in August 2014. This initiative is an integrated project lasting 30 months and is being 
implemented across 19 institutions in 14 countries, and across five Movember regions (Australasia, 
Europe, UK, Canada, USA), as well as being open to other eligible centres (‘candidate centres’). GAP3 
aims to create a global consensus on selection and monitoring of men with low-risk prostate cancer for 
AS; provide and manage a worldwide platform with information and guidelines on AS as an 
acknowledged treatment option for prostate cancer, and to reduce the number of men switching to active 
therapy within 1 year of starting the AS protocol. Milestones of the project include a global AS database 
for clinical, biopsy sample, imaging and biomarker data (including a virtual biobank), as well as 
worldwide tailor-made guidelines, including a web-based platform on AS. At this stage, active 
surveillance ‘is a treatment approach in evolution.’ This initiative will make significant contributions to 
this field of research by offering standard, evidence-based guidelines on AS. Clinicians will be able to use 
these guidelines to more confidently identify men that are suitable for active surveillance and to also 
decide whose prostate cancer has progressed and will, therefore, require treatment. Such guidelines will 
provide reassurance to men that they have made the best treatment choice for their type of disease.  
[H1] Conclusions 
Despite the ample availability of guidelines on AS for patients with prostate cancer, consensus on 
inclusion criteria, surveillance schedules and intervention thresholds is currently lacking. The future of 
AS and its uptake as a management modality will depend on better patient selection and validated 
monitoring schedules to improve the identification of disease progression. Combining existing evidence 
and gathering more long-term evidence is needed in order to derive a broadly supported guideline to 
reduce variation in clinical practice and to optimize clinical decision-making.  
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Review criteria 
Several strategies were used to identify relevant guidelines on active surveillance for localized prostate 
cancer. In April 2014, electronic searches were performed in Medline, Cochrane Central Register of 
Controlled Trials (CENTRAL), Web of Science, CINAHL, PubMed and Google scholar online databases. 
A search strategy was developed in collaboration with an experienced librarian for relevant publications. 
The search string was initially developed in Embase and later adapted for other databases (see appendix 1 
for the full search strategy). The search covered literature published between 2001 and 2014. The goal of 
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this study was to provide a comprehensive overview of existing guidelines, therefore, no restrictions were 
made with regards to nonempirical studies such as literature reviews and conference abstracts. To retrieve 
all the relevant literature, the search string was not restricted by language or date of publication.  
Reference lists of the selected studies were manually screened. Studies were included if they focused on 
prostate cancer or focused on active surveillance of patients with prostate cancer, and contained 
information on, or a reference, to an active surveillance guideline or a guideline on the management of 
prostate cancer in general that potentially includes recommendations on active surveillance. Studies that 
discussed active surveillance study protocols were excluded from the search. The literature search was 
followed by an electronic search of the individual websites of guideline collections, namely the National 
Guidelines Clearinghouse (www.guideline.gov) and Guidelines International Network (www.g-i-n.net)
12
. 
The following search string was used: ‘active surveillance prostate cancer’/ ‘watchful waiting prostate 
cancer’. For the Guidelines International Network database, a more general search string was used: 
‘prostate cancer’. Additionally, the internet was searched. For instance, websites of relevant organizations 
and specialties were examined. This process was repeated until August 2015 to check for recent updates 
and new guideline publications. Guidelines were included if they met the following inclusion criterion: 
the guideline contained recommendations on patient’s eligibility for active surveillance or the type and/or 
frequency of monitoring during active surveillance, and/or criteria for switching from active surveillance 
to definitive therapy. Guidelines that did not fulfil this criterion, or were published before 2005, were 
excluded from our search.  
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Table 1 | Guidelines on use of active surveillance 
Country of 
origin 
Organization (abbreviation) Title 
USA American Urological Association (AUA) Guideline for the Management of Clinically 
Localized Prostate Cancer: 2007 update13 
USA The National Comprehensive Cancer 
Network (NCCN) 
NCCN Guidelines version 2.2014 Prostate 
Cancer (2014)11 
Europe European Association of Urology (EAU) Guidelines on prostate cancer (2014)14 
UK National Institute for Health and Clinical 
Excellence (NICE) 
Prostate cancer: diagnosis and treatment (2014)12 
Germany German Society of Urology (GSU) Interdisziplinäre Leitlinie der Qualität S3 zur 
Früherkennung, Diagnose und Therapie der 
verschiedenen Stadien des Prostatakarzinoms 
(2014)15 
The 
Netherlands 
Dutch Urological Association (DUA) Richtlijn prostaatcarcinoom (2014)16 
Belgium Belgian Healthcare Knowledge Centre 
(KCE) 
A national clinical practice guideline on the 
management of localised prostate cancer (2013)17 
Finland The Finnish Medical Society Duodecim 
(FCCG) 
Prostate cancer (Eturauhassyöpä) (2014)23 
Scotland South East Scotland Cancer Network 
(SCAN) 
SCAN Guideline for Active Surveillance 
(Deferred Radical Treatment) of Early, Low-
Risk, Prostate Cancer (2009)18 
Spain Aragon Institute of Health Sciences (I+CS) Clinical Practice Guideline for Prostate Cancer 
Treatment (2008)19 
Canada Cancer Care Nova Scotia (CCNS) 
 
Guidelines for the Management of 
Prostate Cancer (2006)10 
Canada  Alberta Health Services (AHS) Alberta Health Services Clinical Practice 
Guideline: Prostate Cancer (2014)20 
Canada Cancer Care Ontario (CCO) Program in 
Evidence-Based Care (PEBC) 
Active Surveillance for the Management of 
Localized Prostate Cancer: Guideline 
Recommendations (2015)24 
Singapore National Cancer Centre Singapore (NCCS) Guidelines on Management of Prostate Cancer 
(2013)21 
New Zealand Prostate Cancer Taskforce (PCT) Diagnosis and Management of Prostate Cancer in 
New Zealand Men: Recommendations from the 
Prostate Cancer Taskforce (2012)22 
Australia Prostate Cancer Foundation of Australia 
(PCFA) and Cancer Council Australia  
Draft clinical practice guidelines PSA Testing 
and Early Management of Test-Detected Prostate 
Cancer (2015)25 
 
 
25 
 
 
Table 2 | Eligibility criteria for active surveillance: tumour characteristics  
Guidelines Risk 
category 
Clinical 
stage 
Serum 
PSA 
(ng/ml) 
Biopsy 
Gleason 
Score 
Serum 
PSA 
density 
(ng/mL/g) 
Positive 
cores 
(N) 
Maximum 
extent 
cancer per 
core 
Minimum 
cores 
sampled 
(n) 
Other 
AUA13 Low T1c or 
T2a 
≤10 ≤6 NR NR NR NR  
 Intermediate T2b >10–
20  
7 NR NR NR NR  
 High T2c >20 8–10 NR ≤2 ≤50% 10  
EAU14 Low T1c–T2 ≤10 ≤6 NR ≤2 ≤50% NR  
NCCN11 Very low T1c <10 ≤6 <0.15 <3 ≤50% NR  
 Low T1–T2a <10 ≤6 NR NR NR NR  
NICE12 Low T1–T2a <10 ≤6 NR NR NR NR  
 Intermediate T2b 10–20 7 NR NR NR NR  
GSU15 Low T1c and 
T2a 
≤10 ≤6 NR ≤2 ≤50% 10-12  
DUA16 Low T1c–
T2a 
<10 <7 NR 1 or 2 NR NR  
 Intermediate T2b–c 10–20 7 NR NR NR NR  
 High T3 >20 >7 NR NR NR NR  
KCE17 Low T1–T2a <10 <7 NR NR NR NR  
FCCG23 Low T1a–
T2a 
<10 <7 NR <3 NR 10-12  
 Intermediate T2b 10-20 ≤3+4 NR <3 NR 10-12  
SCAN18 Low T1c <10 ≤3+3, 
no 
Grade 4 
<0.15 NR <50% NR <50% of the 
number of 
biopsy cores 
affected 
CCNS10 Low T1–T2a <10 ≤6 NR NR NR NR  
 Intermediate T2b–
T2c 
10-19 7 NR NR NR NR  
I+CS19 Low T1–T2a ≤10 ≤3+3 <0.15 
ng/ml 
NR <50% >10  
AHS20 Low <T2b <10  <7  NR ≤3 ≤50%  10  
CCO24 Low ≤T2a <10 ≤6 or 
3+4=7 
(for 
selected 
patients) 
NR NR NR NR  
NCCS21 Low ≤T2a <10 ≤6 (no 
Gleason 
grade 4 
or 5) 
<0.15 <3 ≤50% NR  
PCT22 Very low T1a,T1c <10 6 <0.15 <3 <50% NR For men 
younger than 
60 years, a 
more 
conservative 
approach 
may be 
warranted by 
using the 
more 
restrictive 
Epstein 
criteria of 
involvement: 
less than 
one-third of 
 Low T1–T2a <10 6 NR NR NR NR 
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cores 
affected, and 
no more than 
50% 
involvement 
of individual 
cores 
affected 
PCFA25 NR  T1–2 ≤20 6 NR NR NR NR  
AUA, American Urological Association; AHS, Alberta Health Services; CCNS, Cancer Care Nova Scotia; CCO, Cancer Care 
Ontario; DUA, Dutch Urological Association; EAU, European Association of Urology; FCCG, The Finnish Medical Society 
Duodecim; GSU, German Society of Urology; I+CS, Aragon Institute of Health Sciences; KCE, Belgian Healthcare Knowledge 
Centre; NICE, National Institute for Health and Clinical Excellence; NCCN, The National Comprehensive Cancer Network; 
NCCS, National Cancer Centre Singapore; NR, not reported; PEBC, Program in Evidence-Based Care; PCFA, Prostate Cancer 
Foundation of Australia, PCT; Prostate Cancer Taskforce; SCAN, South East Scotland Cancer Network. 
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Table 3 | Eligibility criteria for active surveillance: patient characteristics 
Guidelines Risk 
category 
Age Life 
expectancy 
(years) 
Presence of 
comorbidities/ 
general health 
condition 
Patient 
preferences 
 
 
Other 
 
 
AUA13 Low NR NR Mentioned Mentioned – 
 Intermediate NR NR Mentioned Mentioned – 
 High NR NR NR NR – 
EAU14 Low NR >10 NR NR – 
NCCN11 Very low NR >10 NR NR – 
 Low NR >10 NR NR – 
NICE12 Low NR NR NR Mentioned – 
 Intermediate NR NR NR Mentioned – 
GSU15 Low NR NR NR NR – 
DUA16 Low NR NR NR NR – 
 Intermediate Mentioned Mentioned Mentioned NR – 
 High Mentioned Mentioned Mentioned NR – 
KCE17 Low NR >10 NR Mentioned – 
FCCG23 Low Mentioned Mentioned Mentioned Mentioned – 
 Intermediate Mentioned Mentioned Mentioned Mentioned – 
SCAN18 Low ≤75 >10 (with 
caution in 
those with 
LE of >20) 
NR NR   
CCNS10 Low NR NR NR NR – 
 Intermediate NR NR NR NR – 
I+CS19 Low NR NR Mentioned Mentioned – 
AHS20 Low NR NR NR Mentioned – 
CCO24 Low NR NR NR NR – 
NCCS21 Low NR <10 Mentioned Mentioned – 
PCT22 Very low NR Mentioned Mentioned Mentioned Ultimately a recommendation for 
AS must be based on careful, 
individualised weighing of a 
number of factors: life 
expectancy, disease 
characteristics, general health 
condition, potential side effects 
of treatment, and patient 
preference. 
 
 Low NR Mentioned Mentioned Mentioned 
PCFA NR  NR NR NR NR – 
AHS, Alberta Health Services; AUA, American Urological Association; CCNS, Cancer Care Nova Scotia; CCO, Cancer Care 
Ontario; DUA, Dutch Urological Association; EAU, European Association of Urology; FCCG, The Finnish Medical Society 
Duodecim; GSU, German Society of Urology; I+CS, Aragon Institute of Health Sciences; KCE, Belgian Healthcare Knowledge 
Centre; NCCN, The National Comprehensive Cancer Network; NCCS, National Cancer Centre Singapore; NICE, National 
Institute for Health and Clinical Excellence; NR, not reported; PCFA, Prostate Cancer Foundation of Australia, PCT; Prostate 
Cancer Taskforce; PEBC, Program in Evidence-Based Care; SCAN, South East Scotland Cancer Network. 
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Table 4 | Recommendations for follow-up monitoring  
Guidelin
es 
serum PSA PSA kinetics  
(PSADT, PSAV) 
DRE Rebiopsy mpMRI 
AUA13* NR NR NR NR NR 
EAU14 Mentioned NR Mentioned Mentioned NR 
NCCN11‡ ≥6-monthly 
intervals unless 
clinically 
indicated 
NR ≥12-monthly 
intervals 
unless 
clinically 
indicated 
≤12-monthly intervals 
unless clinically 
indicated, 6-monthly 
intervals if initial biopsy 
<10 cores. 
To be considered if serum 
PSA rises and biopsy 
samples are negative 
NICE12 Year 1: Every 
3–4 months, 
year 2–4: 3–6 
months 
Year 5+: 6 
months 
Measured 
throughout 
surveillance. Can 
include doubling 
time and velocity 
Year 1: 6–12 
months, year 
2–4: 6–12 
months, 
year 5+: 
annually 
Year 1: 12 months, or if 
concerned about clinical 
or serum PSA changes 
At enrollment if not done 
before, if concern exists 
about clinical or PSA 
changes 
GSU15 Year 0–2: every 
3 months, if 
serum PSA is 
stable then 
every 6 months 
Mentioned Year 0–2: 
every 3 
months, if 
serum PSA is 
stable then 
every 6 
months 
Year 0–3: every 12–18 
months, then every 3 
years 
NR 
DUA16* NR NR NR NR NR 
KCE17 Every 6 months NR Every 6 
months 
Within 1 year, after this 
biopsy repeat biopsies 
(timing can currently not 
be defined) 
Imaging every year can be 
considered 
FCCG23§ NR NR NR NR NR 
SCAN18 Year 1: 3-
monthly 
intervals after 
first year, 6-
monthly if 
stable 
PSA doubling time 
after 5 PSA 
measurements 
Minimum 
every 6 
months 
Within 6 months then at 
1,4,7 and 10 years 
NR 
CCNS10 
 
6-monthly NR 6-monthly At 6 months if original 
biopsy <10 cores or 
discordant with clinical 
findings, otherwise within 
18 months, and then 
periodically 
NR 
I+CS19 Every 3 months 
for first 2 years, 
then every 6 
months 
Estimation of PSA 
speed with linear 
regression, using at 
least 5 PSA 
determinations 
extended over at 
least a year 
Every 3 
months for 
first 2 years, 
then every 6 
months 
After 1 year, 4 years, 7 
years (minimum 10 cores 
per biopsy) 
NR 
AHS20 PSA every 3–6 
months, at the 
physician’s 
discretion  
Mentioned DRE 
annually, at 
the 
physician’s 
discretion 
Repeat biopsies 1–2 years 
after initial diagnosis, 
further biopsies every 2–3 
years or as clinically 
indicated 
NR 
CCO24|| Every 3–6 
months 
NR Annually 12–14-core confirmatory 
TRUS biopsy (including 
anterior directed cores) 
within 6–12 months, then 
serial biopsy a minimum 
of every 3–5 years 
Indicated when a patient’s 
clinical findings are 
discordant with pathological 
findings, and for identifying 
occult cancers or changes 
indicative of tumour 
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thereafter progression in patients at 
risk 
NCCS21 3–6 monthly NR Annually Within the first 12–18 
months, or if no adverse 
features after 2 years, 
interval between follow-
up consultations and 
repeat biopsies can be 
increased 
NR 
PCT22 6-monthly, or 3-
monthly if 
concerned about 
progression 
Mentioned Mentioned Within 12 months of 
initial biopsy, or as 
clinically indicated 
NR 
PCFA25* NR NR NR NR NR 
*Guidelines contain no follow-up recommendations. ‡More rigorous follow up recommended in younger than in older men. §Use of 
‘proper’ diagnostics emphasized. ||Daily 5-α reductase inhibitors might have a role in men on active surveillance. AHS, Alberta 
Health Services; AUA, American Urological Association; CCNS, Cancer Care Nova Scotia; CCO, Cancer Care Ontario; DUA, 
Dutch Urological Association; EAU, European Association of Urology; FCCG, The Finnish Medical Society Duodecim; GSU, 
German Society of Urology; I+CS, Aragon Institute of Health Sciences; KCE, Belgian Healthcare Knowledge Centre; mpMRI, 
multiparametric MRI; NCCN, The National Comprehensive Cancer Network; NCCS, National Cancer Centre Singapore; NICE, 
National Institute for Health and Clinical Excellence; NR, not reported; PCFA, Prostate Cancer Foundation of Australia, PCT; 
Prostate Cancer Taskforce; PEBC, Program in Evidence-Based Care; PSADT, PSA doubling time; PSAV, PSA velocity; SCAN, 
South East Scotland Cancer Network. 
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Table 5 | Criteria for switching from active surveillance to definitive therapy 
Guidelines serum 
PSA 
(ng/m
l) 
PSA 
kinetics  
(PSADT, 
PSAV) 
DRE Imaging Rebiopsy 
Gleason Score 
Tumour
-positive 
cores 
(N) 
Cancer 
per 
core 
General 
AUA13* NR NR NR NR NR NR NR NR 
EAU14* NR NR NR NR NR NR NR NR 
NCCN11 NR NR NR NR  4/5 Increase 
in 
number   
Increase 
in 
extent 
per core 
NR 
NICE12‡ NR NR NR NR NR NR NR Disease 
progression 
GSU15 >10  PSADT <3 
yrs 
>cT2a NR >6 >2 >50% NR 
DUA16* NR NR NR NR NR NR NR NR 
KCE17 >10 PSADT<3 
years 
Clinical 
change 
Suspiciou
s lesions 
detected 
NR NR NR NR 
FCCG23 NR PSADT<3 
years 
NR NR >6 >2 NR If reclassified 
to clinically 
relevant 
SCAN18§ NR PSADT 
time <3 
years. 
Progression of 
palpable T2 
disease on 
DRE or 
palpable 
lesions 
appearing. 
NR 4 or 5 NR >50% 
of any 
core, 
>50% 
of cores 
affected 
NR 
CCNS10 
 
NR NR NR NR NR NR NR Disease 
progression  
I+CS1919 NR PSA 
velocity 
>1ng/ml per 
year 
Mentioned NR Mentioned NR NR NR 
AHS20|| NR PSADT <3 
years 
Increase in 
clinical stage 
from baseline 
status 
NR Presence of 
pattern ≥4 
NR >50% NR 
CCO24 NR NR NR NR Gleason ≥7 (4+3 
or 3+4 with 
Gleason pattern 4 
pathology 
accounting for 
>10% total 
tumour) or 3+ 
and/or significant 
increases in the 
volume of 
Gleason 6 tumour 
NR NR NR 
NCCS21|| NR NR Abnormal, or 
change 
observed on 
DRE 
NR Increase in 
Gleason score ≥7 
or any Gleason 
pattern 4 or 5 
>2  >50%  NR 
PCT22* NR NR NR NR NR NR NR NR 
PCFA25* NR NR NR NR NR NR NR NR 
*Guidelines contain no recommendations for switching from active surveillance to definitive therapy. ‡ Guidelines recommend 
consideration of personal preferences, comorbidities and life expectancy §Presence of bilateral disease is considered an appropriate 
criterion for switching to definitive therapy ||Guidelines recommend consideration of personal preferences. AHS, Alberta Health 
Services; AUA, American Urological Association; CCNS, Cancer Care Nova Scotia; CCO, Cancer Care Ontario; DUA, Dutch 
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Urological Association; EAU, European Association of Urology; FCCG, The Finnish Medical Society Duodecim; GSU, German 
Society of Urology; I+CS, Aragon Institute of Health Sciences; KCE, Belgian Healthcare Knowledge Centre; NCCN, The National 
Comprehensive Cancer Network; NCCS, National Cancer Centre Singapore; NICE, National Institute for Health and Clinical 
Excellence; NR, not reported; PCFA, Prostate Cancer Foundation of Australia, PCT; Prostate Cancer Taskforce; PEBC, Program in 
Evidence-Based Care; PSADT, PSA doubling time; PSAV, PSA velocity; SCAN, South East Scotland Cancer Network. 
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Table 6. Summary of guidelines on active surveillance  
Guide
lines 
Risk 
cate
gory 
Tumour characteristics Patient 
characte
ristics 
Follow-up monitoring Criteria for switching from active 
surveillance to definitive therapy 
AUA1
3 
 
Low Tumour stage T1c or T2a, 
serum PSA ≤10 ng/ml, 
biopsy Gleason score ≤6 
NR NR NR 
 Inter
medi
ate 
Tumour stage T2b, serum 
PSA >10–20 ng/ml, biopsy 
Gleason score of 7 
NR 
 High Tumour stage T2c, serum 
PSA >20 ng/ml, 8–10 
ng/ml, ≤2 tumour-positive 
biopsy core samples, ≤50% 
of tumour positivity per 
biopsy core, 10 cores 
sampled 
NR 
EAU1
4 
 
Low Tumour stage T1c–T2, 
serum PSA ≤10 ng/ml,  
biopsy Gleason score ≤6, 
≤2 tumour-positive biopsy 
core samples, ≤50% 
tumour positivity per 
biopsy core 
LE>10 
years 
Serum PSA, DRE and rebiopsy all 
mentioned  
NR 
NCC
N11 
 
Very 
low 
Tumour stage T1c, serum 
PSA <10 ng/ml, biopsy 
Gleason score ≤6, PSA 
density <0.15, <3 tumour-
positive biopsy core 
samples, ≤50% tumour 
positivity per biopsy core 
LE >10 Serum PSA ≤6-monthly unless 
clinically indicated, DRE ≤12-
monthly unless clinically indicated, 
rebiopsy ≤12-monthly unless 
clinically indicated or at 6 months 
if the initial biopsy sample had <10 
cores, MRI mentioned 
Rebiopsy sample Gleason score 
contains 4 or 5 grade disease, 
increased number of tumour-
positive cores or increased extent 
of cancer per core  
 Low Tumour stage T1–T2a, 
serum PSA <10 ng/ml, 
biopsy Gleason score ≤6 
LE >10 
NICE
12 
 
Low Tumour stage T1–T2a, 
serum PSA <10 ng/ml, 
biopsy Gleason score ≤6 
NR Serum PSA every 3–4 months 1 
year post-diagnosis, every 3–6 
months 2–4 years post-diagnosis, 
and thenevery 6 months post-
diagnosis, PSA kinetics (PSADT 
and PSAV) to be measured 
throughout active surveillance, 
DRE every 6–12-months 1–4 years 
post-diagnosis,  and then annually 
thereafter, rebiopsy sampling 12 
months after diagnosis or if 
concerns exist about clinical or 
serum PSA changes, MRI at 
enrollment if not done before or in 
the presence of concern about 
clinical or PSA changes 
Switching recommended if disease 
progression observed, also taking 
into account the patient’s life 
expectancy, treatment preferences 
and comorbidities 
 Inter
medi
ate 
Tumour stage T2b, serum 
PSA 10–20 ng/ml, biopsy 
Gleason score of 7 
NR 
GSU1
5 
 
Low Tumour stage T1c–T2a, 
serum PSA ≤10 ng/ml, 
biopsy Gleason score ≤6, 
≤2 tumour positive biopsy 
core samples, ≤50% 
tumour positivity per 
biopsy core, 10–12 cores 
sampled 
NR Serum PSA every 3 months 0–2 
years post-diagnosis, every 6 
months thereafter if levels remain 
stable, PSA kinetics mentioned, 
DRE every 3 months 0–2 years 
post-diagnosis then every 6 months 
thereafter, if PSA stable, 
rebiopsy every 12–18 months 
within 3 years post-diagnosis, then 
every 3 years thereafter 
Switching recommended if serum 
PSA >10 ng/ml, PSADT <3 years, 
tumour stage >cT2a, rebiopsy 
Gleason score >6, >2 tumour-
positive biopsy sample cores, 
>50% cancer per biopsy sample 
core 
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DUA1
6 
 
Low Tumour stage T1c–T2a, 
serum PSA <10 ng/ml, 
biopsy Gleason score <7, 1 
or 2 tumour-positive 
biopsy core samples 
NR NR NR 
 Inter
m 
Tumour stage T2b–c, 
serum PSA 10-20 ng/ml, 
biopsy Gleason score of 7 
mention
ed 
 High Tumour stage T3, serum 
PSA >20 ng/ml, biopsy 
Gleason score of >7 
Age and 
LE 
mention
ed 
KCE1
7 
 
Low Tumour stage T1–T2a, 
serum PSA <10 ng/ml, 
Gleason score of <7 
LE >10 Serum PSA every 6 months, DRE 
every 6 months,  
rebiopsy within 1-year and repeated  
thereafter (timing can currently not 
be defined), annual MRI  
 
Switching recommended if serum 
PSA >10ng/ml, PSADT <3 years, 
clinical change detected during 
DRE, or if suspicious lesions 
observed during imaging 
FCC
G23 
 
Low Tumour stage T1a–T2a, 
serum PSA <10 ng/ml, 
Gleason score <7, <3 
tumour-positive biopsy 
core samples, 10–12 cores 
sampled 
Mention
ed 
Serum PSA, PSA kinetics, DRE 
and rebiopsy all mentioned 
 
Switching recommended if PSADT 
<3 years, rebiopsy Gleason score 
>6, >2 tumour-positive biopsy 
sample cores are detected, or if 
disease is reclassified as being 
clinically relevant 
 Inter
m 
Tumour stage T2b, serum 
PSA 10–20 ng/ml, biopsy 
Gleason score of ≤3+4, <3 
tumour-positive biopsy 
core samples, 10–12 cores 
sampled 
Age and 
LE 
mention
ed 
SCA
N18 
 
Low Tumour stage T1c, serum 
PSA <10 ng/ml, biopsy 
Gleason score of ≤3+3, no 
Grade 4, PSA density 
<0.15, <50% tumour 
positivity per biopsy core, 
<50% of the number of 
biopsy cores affected 
Age ≤75 
LE >10 
Serum PSA every 3 months within 
1 year post-diagnosis, 6-monthly 
sampling thereafter if stable, 
PSADT to be measured after 5 PSA 
results, ≤6 monthly DRE, rebiopsy 
within 6-months post-diagnosis 
then at 1,4,7 and10 years 
Switching recommended if: 
PSADT <3 years, progression of 
palpable T2-stage disease on DRE 
or palpable lesions appearing, 
emergence of Gleason grade 
pattern 4 or 5, >50% spread of 
cancer in any biopsy core sample, 
>50% of core samples affected, or 
if  disease is bilateral 
CCN
S10 
 
Low Tumour stage T1–T2a, 
serum PSA <10 ng/ml, 
biopsy Gleason score of ≤6 
NR Serum PSA every 6 months, DRE 
every 6 months, rebiopsy at 6 
months if original biopsy sample 
had <10 cores or findings are 
discordant with clinical findings, 
within 18 months otherwise then 
periodically thereafter 
Switching recommended if disease 
progression observed 
 Inter
medi
ate 
Tumour stage T2b–T2c, 
serum PSA 10–19 g/ml, 
biopsy Gleason score of 7 
NR 
I+CS1
9 
 
Low Tumour stage T1–T2a, 
serum PSA ≤10 ng/ml  
biopsy Gleason score of 
≤3+3, serum PSA density 
of <0.15 ng/ml, <50% 
tumour positivity per 
biopsy core, >10 cores 
sampled 
 
NR Serum PSA Every 3 months within 
0–2 years post-diagnosis, then 6-
monthly thereafter,“Estimation of 
PSA speed with linear regression, 
using at least 5 PSA determinations 
extended over at least a year”, DRE 
every 3 months within 0–2 years 
post-diagnosis then 6-monthly 
thereafter, Rebiopsy sampling after 
1 year, 4 years and 7 years 
(minimum 10 cores per biopsy 
sample) 
PSAV >1 ng/ml per year, DRE, 
rebiopsy sample Gleason score, 
number of tumour-positve biopsy 
sample cores, and maximum extent 
of cancer per core all mentioned 
 
AHS2
0 
 
Low Tumour stage <T2b, serum 
PSA <10 ng/ml, biopsy 
Gleason score of <7, ≤3 
tumour-positive biopsy 
NR Serum PSA every 3–6 months, at 
the physician’s discretion,  
serum PSA kinetics mentioned 
DRE annually, at the physician’s 
Switching recommended if PSAD 
<3 years, increase in clinical stage 
from baseline status is observed on 
DRE, Gleason pattern ≥4 observed 
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core samples ≤50% tumour 
positivity per biopsy core, 
>10 cores sampled 
discretion 
repeat biopsy sampling 1–2 years 
after initial diagnosis, 
further biopsy sampling every 2–3 
years, or as clinically indicated 
on analysis of rebiopsy samples, 
>50% of cancer observed per core 
biopsy sample, also taking into 
account patient preferences 
CCO2
4 
 
Low Tumour stage ≤T2a, serum 
PSA <10 ng/ml, biopsy 
Gleason score of ≤6 or 
3+4=7 (for selected 
patients) 
NR Serum PSA every 3–6 months,  
DRE measured annually 
12-14-core confirmatory TRUS 
biopsy within 6–12 months post-
biopsy, then serial biopsy a 
minimum of every 3–5 years 
thereafter, MRI mentioned  
Rebiopsy sample Gleason score ≥7 
(4+3 or 3+4) with pattern 4 
pathology accounting for >10% of 
the total tumour or 3+ and/or 
significant increases in the 
volume of Gleason 6 tumours 
NCC
S21 
 
Low Tumour stage ≤T2a, serum 
PSA <10 ng/ml, biopsy 
Gleason score of ≤6 (no 
Gleason grade 4 or 5), 
serum PSA density of 
<0.15, <3 tumour-positive 
biopsy core samples, ≤50% 
tumour positivity per 
biopsy core 
LE  <10 
years 
Serum PSA measurements every 3–
6 months, annual DRE, rebiopsy 
sampling within the first 12–18 
months post-diagnosis, if no 
adverse features are observed after 
2 years, this interval can be 
increased 
Switching recommended of 
abnormalities or change observed on 
DRE, increase in GS ≥7 or any pattern 
4 or 5 observed on rebiopsy sampling, 
>2 tumour positve biops core samples, 
>50% of cancer observed per core 
biopsy sample, also taking into 
account patient preferences  
PCT22 
 
Very 
low 
Tumour stage T1a,T1c, 
serum PSA <10 ng/ml, 
biopsy Gleason score of 6, 
PSA density <0.15, <3 
tumour positive biopsy 
core samples, <50% 
tumour positivity per 
biopsy sample 
LE, 
disease 
characte
ristics, 
general 
health 
conditio
n, 
potentia
l side 
effects 
of 
treatme
nt, 
patient 
preferen
ce 
mention
ed  
Serum PSA measurements every 6 
months, or every 3 months if 
concerns exist regarding disease 
progression, PSA kinetics and DRE 
mentioned, rebiopsy sampling 
recommended within 12 months of 
initial biopsy sampling or as 
clinically indicated 
NR 
 Low Tumour stage T1–T2a, 
serum PSA <10 ng/ml, 
biopsy Gleason score of 6 
LE 
mention
ed 
PCFA
25 
  
 Tumour stage T1-T2, 
serum PSA ≤20 ng/ml 
biopsy Gleason score of 6 
NR NR NR 
AHS, Alberta Health Services; AUA, American Urological Association; CCNS, Cancer Care Nova Scotia; CCO, Cancer Care 
Ontario; DUA, Dutch Urological Association; EAU, European Association of Urology; FCCG, The Finnish Medical Society 
Duodecim; GSU, German Society of Urology; I+CS, Aragon Institute of Health Sciences; KCE, Belgian Healthcare Knowledge 
Centre; LE, life expectancy; NCCN, The National Comprehensive Cancer Network; NCCS, National Cancer Centre Singapore; NICE, 
National Institute for Health and Clinical Excellence; NR, not reported; PCFA, Prostate Cancer Foundation of Australia, PCT; 
Prostate Cancer Taskforce; PEBC, Program in Evidence-Based Care; PSADT, PSA doubling time; PSAV, PSA velocity; SCAN, 
South East Scotland Cancer Network 
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Box 1. Members of the Movember Global Action Plan consortium 
 
 
Ehdaie, Behfar Memorial Sloan Kettering Cancer Center, New York, USA 
Fahey, Michael Epworth HealthCare, Melbourne, Australia 
Filson, Christopher Emory University School of Medicine, Atlanta, USA 
Frydenberg, Mark Monash University, Melbourne, Australia 
Gnanapragasam, Vincent Cambridge University Hospitals NHS Trust, Cambridge, UK 
Kakehi, Yoshiyuki Kagawa University Faculty of Medicine, Kagawa, Japan 
Kattan, Mike Cleveland Clinic, Cleveland, USA 
Klotz, Laurence University of Toronto, Sunnybrook Health Sciences Centre, Toronto, Canada 
Lophatananon, Artitaya University of Manchester, Manchester, UK 
Malouf, David Sydney Prostate Cancer Center, Sydney, Australia 
Moore, Caroline University College London & University College London Hospitals Trust, London, UK 
Muir, Kenneth University of Manchester, Manchester, UK 
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Box 2. Unresolved issues in active surveillance  
Inclusion 
 Inclusion of men with stage T2b–c or T3, serum PSA >10 ng/ml and with Gleason 7 (3+4) cancer 
 Serum PSA density, the minimum number of cores sampled, the patient’s life expectancy, the 
presence of comorbidities, and patient’s preferences as risk stratification tools 
 Potential role of new biomarkers in selecting men for active surveillance (including genomics) 
 The role of MRI in selecting men for active surveillance 
 The role of quality of life in the decision to initially pursue active surveillance rather than active 
treatment 
 A validated, multivariate risk assessment tool for definitions of ‘low-risk’ disease 
Patient monitoring and triggers for treatment 
 Optimal timing of surveillance monitoring strategies (frequency of serum PSA measurement, 
DRE and repeat biopsy) while on active surveillance 
 The role of multiparametric MRI in predicting prostate cancer progression 
 The role of serum PSA kinetics as a trigger for intervention 
 Definitions of disease reclassification and progression 
 The role of novel biomarkers and monitoring tools in risk assessment during active surveillance 
 The role of quality of life in the decision to switch from active surveillance towards active 
treatment 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
